
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Watson Pharmaceuticals has received FDA approval on its abbreviated new drug application for a generic version of testosterone gel 1% CIII.
Watson Pharmaceuticals has received FDA approval on its abbreviated new drug application for a generic version of testosterone gel 1% CIII. The drug is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.





